Mesenchymal stem cell injections for the treatment of perianal crohn's disease: What we have accomplished and what we still need to do

Amy Lightner, William Alvis Faubion

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.

Original languageEnglish (US)
Pages (from-to)1267-1276
Number of pages10
JournalJournal of Crohn's and Colitis
Volume11
Issue number10
DOIs
StatePublished - Oct 1 2017

Keywords

  • Crohn's disease
  • Perianal fistula
  • Stem cells

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Mesenchymal stem cell injections for the treatment of perianal crohn's disease: What we have accomplished and what we still need to do'. Together they form a unique fingerprint.

  • Cite this